Regulatory impact assessment for every change control, market by market, with the rule cited
Every plant change traced to each registration it touches, with the filing each country needs proposed and cited.
See one case, screen by screen ↓A change control lands from the QMS: a duplicate bioreactor line, a tighter dissolution limit, a second packaging site. Before it can be implemented, regulatory CMC has to say what it means for every registration — which presentations in which countries name the site or element that changes, and what each agency wants: a Type IB in the EU, a CBE-30 in the US, a partial change approval in Japan, a Type II amendment in South Africa.
So someone pulls the registration list from RIM, opens Module 3 for each market, checks each country's variation rules and works out when the last approval will land — for one product registered in 21 markets, most of a day per change. And it is easy to miss the market whose dossier is out of date, or the one that never registered the site, where new material must not ship.
Estimated split, in hours, for one change touching about 20 markets — by hand and with the solution.
Six specialist agents read the change, find every registration, quote each dossier, classify each market and plan the runway; the regulatory CMC lead decides each market.
Plant 3 in Leiden wants a second 12,000 L bioreactor train for Veltrimab — Line B, a duplicate of Line A. Here is how the assessment goes, screen by screen, in the working solution.
Priya opens the solution to one change waiting for assessment, one ready for her review, one waiting for second approval and 47 filing tasks open across 21 markets. CC-2026-0417 sits at the centre: 36 registrations touched in 19 markets, 19 filings, each small dot a registration of the 100 mg vial, 150 mg syringe or 300 mg pen.
Needs you: “Türkiye dossier out of date — Names BCS 4.1 · fix in the Line B filing.”
Omar Haddad raised the change in the QMS on Sep 29. The agents read it, found 39 Veltrimab registrations in 21 markets and quoted the registered text in each — 10 markets need prior approval, 9 notify and wait, 2 are not affected. Each cell is a registration, coloured by what that country needs, with the expected approval date underneath.
“Rule classifier — 21 proposals · 2 below 75% confidence.”
Priya presses “Confirm the clear ones (14)”. Every proposal at or above 80% confidence, with no flag on it, is confirmed under her name. Seven stay open, and four of them are flagged for her call: Türkiye, Japan, Argentina and Saudi Arabia.
“Never automatic — you press the button and it is recorded under your name.”
The approval matters state the culture step runs in one 12,000 L production line at Leiden, and in the March 2023 consultation PMDA said an added drug-substance line is handled as a partial change. The classifier proposes a partial change approval — 12 months, submission Dec 2026, approval Dec 2027 — and shows the alternative it considered.
“Minor change notification — if PMDA agrees the line count is descriptive, not an approval matter. Ask Kenji Mori to confirm in a pre-consultation.”
The Turkish dossier still names bioreactor control system BCS 4.1. Line A has run BCS 5.0 since CC-2024-0211, filed in every other market. The registered text disagrees with the approved change history, so the matcher flags it: correct it in the same Type IB filing. Priya opens a correction task for Dana Okafor, the registration data steward.
The MFDS licence lists Plant 7 — Singapore as the only drug-substance site; so does the COFEPRIS registration. Leiden is not in either licence, so the change does not touch them — and Line B material must not ship there. The supply allocation plan already keeps Singapore supply for both.
A not-affected market always gets a supply note.
Each market's submission and approval, from three years of company history and the sequencing rules: Saudi Arabia files 30 days after the EU decision, Singapore once the EU and the US have both approved. First approvals in Jan 2027, 90% of volume able to take Line B material by Feb 2028, the last market — South Africa — in Jun 2029. One button sends the runway to supply planning.
The assessment writer drafts the regulatory impact assessment in the company template — the change, the registered elements touched, the filing by market with its rule, supply and sequencing, the conclusion. Priya signs with her password and the meaning of the signature: “I approve this regulatory impact assessment”. 18 markets decided by her, 3 accepted as proposed, 19 filings to open.
“10 markets need prior approval, so the assessment goes to Dr. Maya Chen for second approval before filing tasks open.”
Ten markets need prior approval, and the rule asks for a second approval at five or more. Maya sees the ten markets — Japan, China, Taiwan, Singapore, Australia, India, Brazil, Colombia, Argentina, South Africa — and any category the reviewer changed, with the reason. She approves with her password, and the approval is recorded under her name.
Nineteen filing tasks open, one per market, each with its category, owner, submit-by month and expected approval: Priya Raman for the US and Canada, Hanna Berg for the EU, the UK and Switzerland, Lena Ortiz for Türkiye, Kenji Mori for Japan, Li Wen for China and Taiwan. The approved assessment and its dates go back to the change control in the QMS.
“Approved — 19 filing tasks opened · QMS change control updated.”
The same change, seen by the people who carry it from the plant to the agencies — what their week looked like, and what it looks like now.
Six specialist agents read the change, find every registration, quote each dossier, classify each market and plan the runway; the regulatory CMC lead decides each market.
Reads each new change control from the QMS and states what changes, for which product and presentation, and which registered elements it may touch, with the CTD section.
Finds every active registration of the product in the registration records — by presentation and country, including those under renewal — with the sites and elements each one registers.
Opens each country's registered dossier and quotes the exact text the change touches; marks registrations that do not include what changes, and dossiers that disagree with today's process.
Applies each country's rule book to propose the local filing category, cites the rule entry and any past agency advice, gives a confidence and names the alternative it considered.
Estimates submission and approval dates per market from three years of company history and the sequencing rules, and the share of volume that can take the changed material over time.
Writes the regulatory impact assessment memo in the company template from the decided markets, and opens one filing task per market with category, rule, documents needed and target date.
Decides each market; head of regulatory CMC co-signs big changes. The agents propose; a named person decides.
Ask in plain words — or tell it what to change. It answers from the change controls, the 21 country rule books, the registered dossiers and the supply plan, and cites the passage behind every answer.
Which markets need prior approval for Line B?
10 of 21: Australia (Cat 3, Aug ’27), Singapore (MAV-2, Sep ’27), Taiwan (Oct ’27), India (Nov ’27), Japan (PCA, Dec ’27), Argentina (Dec ’27), Colombia (Jan ’28), China (Feb ’28), Brazil (Apr ’28) and South Africa (Type II, Jun ’29). The US, the EU, the UK, Switzerland and Canada need a notify-and-wait filing only — Line B copies Line A.
When can Line B material ship everywhere?
In stages. With filings in Dec 2026: Jan 2027, the US and the EU approve and 71% of volume can take Line B material; Feb 2028, 90% of volume, when China approves; Jun 2029, the last market, South Africa (Type II amendment, about 30 months). South Korea and Mexico register only Plant 7 — Singapore, so Line B material never ships there unless their registrations add Leiden.
Why is Japan a partial change approval?
Because the line count is written into the Japanese approval: the approval matters say the culture step runs in one 12,000 L production line at Leiden, and in the March 2023 consultation PMDA said an added drug-substance line is handled as a partial change. Confidence is 71% because PMDA could still treat the line count as descriptive — Kenji Mori can test that in a pre-consultation.
Hold UAE and Israel filings until the EU approves
Done. New sequencing rule: the UAE and Israel file 30 days after the EU decision, with the EU approval letter. For CC-2026-0417 both submissions move from Dec ’26 to Feb ’27; the 90% of volume date does not move (Feb 2028). The rule is live in Settings and on the audit trail.
13 screens from the working solution, on its sample data. Pick one to see it large.
Who signs, when a second signature is needed and how markets are sequenced are settings, not a project.
| Setting | Default | Choose from |
|---|---|---|
| Signs the impact assessment | Priya Raman | Priya Raman · Dr. Maya Chen |
| Second approval when prior approval is needed in | 5 markets or more | 3 · 5 · 8 markets |
| Second approver | Dr. Maya Chen | Dr. Maya Chen · Omar Haddad |
| Registered-detail corrections go to | Dana Okafor | Dana Okafor · Priya Raman |
| “Confirm the clear ones” includes proposals at or above | 80% confidence | 90 · 85 · 80 % |
| Quote the registered text for every market | On | On · Off |
| Change a proposed category only with a reason | On | On · Off |
| Sequencing rules | Saudi Arabia after EU · Singapore after EU and US | Add a rule |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample products and registrations · “target” = the design goal, measured in the live solution · “estimated” = our estimate, including the by-hand time · “typical” = a published industry study of post-approval change timelines, as quoted in the working solution: about 39 months to reach 90% approval in Africa and the Middle East · Sources: ISPE, Evaluation of post-approval CMC change timelines (2023) · ICH Q12 · 21 CFR 314.70 / 601.12. People named on this page are characters in the working solution; its products, plants and registrations are sample data.
It is the regulatory CMC answer to a manufacturing or quality change: which registrations the change touches, in which countries, and what filing each agency needs before the change can be implemented there. The Change Control Regulatory Impact Assessor produces it as a product × country matrix, a signed memo and a filing task per market.
The rule classifier looks up the change type and the registered element in each country's rule book — Type IA, IB or II in the EU, CBE-30 or prior approval supplement in the US, partial change approval or minor change notification in Japan — and proposes the local category with the rule entry cited, a confidence and the alternative it considered.
No. Every category is a proposal. The regulatory CMC lead confirms, changes or marks each market not affected; proposals below 75% confidence or with a flag wait for her, and a changed category needs a reason that goes into the memo and the audit trail.
The dossier matcher compares the registered detail with the approved change history. When they disagree — a dossier still naming an old control system, for example — it flags the market and the registration data steward gets a correction task, so the fix can go in the same filing.
Yes. A market whose registration does not include what changes is marked not affected, with a supply note: changed material must not ship there. The filing plan shows the share of volume that can ever take the change.
The regulatory CMC lead signs with a password and the meaning of the signature, recorded in the audit trail. When a change needs prior approval in five or more markets — a setting — the Head of Regulatory CMC gives a second approval before filing tasks open.
Your quality management system for change controls, your registration records, your dossier archive of registered Module 3 and local approval documents, and the supply allocation plan. The approved assessment and its dates go back to the change control in the QMS.
The Agentic Solution Engine builds and deploys it from your requirements — your registrations, dossiers, country rule books and a sample of past change controls — and it goes live once every quality gate has passed. We will walk you through it on your own change controls first.
Every agency change reaches the right team within hours, translated and cited.
1-min filmSubmission SummariesModule 2 summaries drafted in weeks, every statement cited to its source page.
1-min filmAgency ResponsesEvery agency question gets a cited first draft within hours, consistent with every past answer.
1-min filmWe’ll run the Change Control Regulatory Impact Assessor on a sample of your own past change controls and registrations.